447 related articles for article (PubMed ID: 25263564)
21. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells.
Schwarze SR; Fu VX; Desotelle JA; Kenowski ML; Jarrard DF
Neoplasia; 2005 Sep; 7(9):816-23. PubMed ID: 16229804
[TBL] [Abstract][Full Text] [Related]
22. Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.
Simova J; Sapega O; Imrichova T; Stepanek I; Kyjacova L; Mikyskova R; Indrova M; Bieblova J; Bubenik J; Bartek J; Hodny Z; Reinis M
Oncotarget; 2016 Aug; 7(34):54952-54964. PubMed ID: 27448982
[TBL] [Abstract][Full Text] [Related]
23. Cellular senescence as a possible link between prostate diseases of the ageing male.
Fiard G; Stavrinides V; Chambers ES; Heavey S; Freeman A; Ball R; Akbar AN; Emberton M
Nat Rev Urol; 2021 Oct; 18(10):597-610. PubMed ID: 34294916
[TBL] [Abstract][Full Text] [Related]
24. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer.
Li D; Zhang Y; Xie Y; Xiang J; Zhu Y; Yang J
Cancer Gene Ther; 2013 Apr; 20(4):251-9. PubMed ID: 23470565
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
[TBL] [Abstract][Full Text] [Related]
26. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.
Di Mitri D; Mirenda M; Vasilevska J; Calcinotto A; Delaleu N; Revandkar A; Gil V; Boysen G; Losa M; Mosole S; Pasquini E; D'Antuono R; Masetti M; Zagato E; Chiorino G; Ostano P; Rinaldi A; Gnetti L; Graupera M; Martins Figueiredo Fonseca AR; Pereira Mestre R; Waugh D; Barry S; De Bono J; Alimonti A
Cell Rep; 2019 Aug; 28(8):2156-2168.e5. PubMed ID: 31433989
[TBL] [Abstract][Full Text] [Related]
27. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
28. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
[TBL] [Abstract][Full Text] [Related]
29. Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.
Korsten H; Ziel-van der Made AC; van Weerden WM; van der Kwast T; Trapman J; Van Duijn PW
PLoS One; 2016; 11(1):e0147500. PubMed ID: 26807730
[TBL] [Abstract][Full Text] [Related]
30. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models.
Lin YX; Wang Y; Ding J; Jiang A; Wang J; Yu M; Blake S; Liu S; Bieberich CJ; Farokhzad OC; Mei L; Wang H; Shi J
Sci Transl Med; 2021 Jun; 13(599):. PubMed ID: 34162754
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
33. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer.
Tanaka M; Rosser CJ; Grossman HB
Cancer Detect Prev; 2005; 29(2):170-4. PubMed ID: 15829377
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
[TBL] [Abstract][Full Text] [Related]
35. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
36. Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells.
Colucci M; Zumerle S; Bressan S; Gianfanti F; Troiani M; Valdata A; D'Ambrosio M; Pasquini E; Varesi A; Cogo F; Mosole S; Dongilli C; Desbats MA; Contu L; Revankdar A; Chen J; Kalathur M; Perciato ML; Basilotta R; Endre L; Schauer S; Othman A; Guccini I; Saponaro M; Maraccani L; Bancaro N; Lai P; Liu L; Pernigoni N; Mele F; Merler S; Trotman LC; Guarda G; Calì B; Montopoli M; Alimonti A
Cancer Cell; 2024 Apr; 42(4):646-661.e9. PubMed ID: 38428412
[TBL] [Abstract][Full Text] [Related]
37. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
38. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
39. Gata3 antagonizes cancer progression in Pten-deficient prostates.
Nguyen AH; Tremblay M; Haigh K; Koumakpayi IH; Paquet M; Pandolfi PP; Mes-Masson AM; Saad F; Haigh JJ; Bouchard M
Hum Mol Genet; 2013 Jun; 22(12):2400-10. PubMed ID: 23428429
[TBL] [Abstract][Full Text] [Related]
40. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
